Unlocking The Potential For a Better Life

Medlab Clinical LTD (ASX.MDC) is an Australian based publicly listed biotechnology company with a portfolio of novel medicine candidates enhanced by its patented medicine delivery platform NanoCelle®.

NanoCelle® is wholly owned by Medlab Clinical and is used to enhance a wide range of active ingredients, with commercial opportunities in pharmaceuticals, generic medicines, cosmetics, nutraceuticals, and textiles. This pioneering delivery platform allows for the development and commercialisation of new products with enhanced medical properties, including increased efficacy, safety, patient compliance and stability. NanoCelle® underpins our growth strategy by offering near-term partnering opportunities whilst enhancing our pharma portfolio.

Medlab’s products are proudly validated by research and supported by a growing patent portfolio. Our team of scientists, researchers and doctors are dedicated to building products that are scientifically optimised to deliver more for human health and beyond. Our pipeline comprises both small and large molecules ranging from repurposing generic medicines to enhancing the delivery of immunotherapies.

ASX Announcements
Review Medlab Clinical's Financial reports, Annual reports and all other ASX Announcements
Read more
Latest Press Releases
Government grant to apply NanoCelle® to an RNA nasal vaccine
Medlab (ASX:MDC) receives Government grant to apply NanoCelle® to an RNA nasal vaccine in collaboration with University of NSW (UNSW) and Macquarie University (MQ) to fight COVID-19 future potential epidemics.
Read more
Medlab Clinical raises $15 million and Leading Executive Joins Board
Medlab Clinical successfully raised $15 million via a two-tranche placement.
Read more
Novartis’ Managing Director of Oncology (ANZ/NZ) joins Medlab Clinical board
Medlab Clinical appoints Novartis' Managing Director of Oncology for Australia and New Zealand as Non-Executive Director.
Read more
Medlab to be granted European patent for NanoCelle® drug delivery platform
European Patent Office issues Notice of Intention to grant Medlab Clinical patent for NanoCelle® drug delivery platform
Read more


Sign up for Investor updates

Stay up-to-date with the latest investor news, presentations and videos from Medlab sent directly to your email address.

* indicates required field


Have a question?

Investor Inquiries:
Laine Yonker, Medlab US
Investor Relations

Email

General Inquiries:
Email